Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): Real-world experience in three European countries

British Journal of Ophthalmology

Volumn 103, Issue 8, 2019, Pages 1072-1077

  Chakravarthy, Usha ^a   Taylor, Simon R ^b   Koch, Frank H Johannes ^c   Castro De Sousa, João Paulo ^d   Bailey, Clare ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

^d Leiria District Hospital   (Portugal)

^e BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

clinical trial; macula; pharmacology; retina

Indexed keywords

FLUOCINOLONE ACETONIDE; RANIBIZUMAB; GLUCOCORTICOID;

AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE CLASSIFICATION; DRUG EFFICACY; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PORTUGAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG IMPLANT; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; DIABETIC RETINOPATHY; DRUG IMPLANTS; EUROPE; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85053778659     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2018-312284     Document Type: Article

References (23)

1. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy XV. Ophthalmology 1995;102:7-16.
2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
3. Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151-69.
4. Dong N, Xu B, Wang B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 2013;19:1734-46.
5. Dong N, Xu B, Chu L, et al. Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One 2015;10:e0125329.
6. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016;2016:1-17.
7. Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with as-needed ranibizumab after initial monthly therapy: long-Term outcomes of the phase III RIDE and RISE Trials. Ophthalmology 2015;122:2504-13.
8. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011;152:686-94.
9. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32.
10. Campochiaro PA, Brown DM, Pearson A, et al. Long-Term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35.
11. Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye 2017;31:1707-15.
12. Medicines and Healthcare Products Regulatory Agency. 2018. Iluvien 190 micrograms intravitreal implant in applicator. Public Assessment Report. PL 41472/0001; UK/H/3011/001/E01. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf.
13. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015;314:2137-46.
14. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
15. Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep 2015;15:99.
16. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-59.
17. Diabetic Retinopathy Clinical Research Network ( DRCR. net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51.
18. Parrish RK, Campochiaro PA, Pearson PA, et al. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging Retina 2016;47:426-35.
19. Parrish RK, Traverso CE, Green K, et al. Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants. Ophthalmic Surg Lasers Imaging Retina 2016;47:418-25.
20. Bertelmann T, Schulze S. Long-Term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Ther 2015;4:51-8.
21. Elaraoud I, Andreatta W, Kidess A, et al. Use of fluocinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3.
22. Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: A case series. Clin Ophthalmol 2015;9:801-11.
23. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-Term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-903.